Perimenopause and HRT on TikTok: fact vs. viral noise

What did @hormoneguru actually say?

In a video with over 837,000 views, a self-described integrative gynecologist listed five things she would never do in hormone practice. The claims range from refusing to prescribe oral estrogen because it raises sex hormone-binding globulin (SHBG), to arguing that estrogen-only therapy causes breast cancer even in women without a uterus, to insisting that a TSH alone is insufficient for thyroid evaluation. She wraps up with a lifestyle pitch: sleep, diet, and movement matter alongside any prescription.

Some of this is grounded in real physiology. Some of it is a significant overreach of the evidence. And at least one claim, that estrogen alone increases breast cancer risk in all women, misrepresents the actual data badly enough that it could discourage women from taking a therapy that may genuinely help them.

Does the science back this up?

Partially, yes. The SHBG point is real science, but the clinical consequences are overstated. The breast cancer framing is where things go off the rails.

Oral estradiol does raise SHBG. That is not disputed. A study by Campagnoli et al. (2005, Journal of Steroid Biochemistry and Molecular Biology) confirmed that oral estrogens increase hepatic SHBG production more than transdermal routes do. This can reduce free testosterone levels, which is relevant for women already dealing with low androgens. So her preference for transdermal estrogen is clinically defensible, if slightly more nuanced than she presents it.

The breast cancer claim is a different story. She cites the Nurses' Health Study and the E3N-EPIC cohort to argue that "estrogen alone" increases breast cancer risk. But the Women's Health Initiative, the largest randomized controlled trial on the subject, found the opposite: conjugated equine estrogen alone in hysterectomized women was associated with a reduced risk of breast cancer (Anderson et al., 2004, JAMA). The E3N cohort she references actually found increased risk specifically with synthetic progestins combined with estrogen, not estrogen alone.

What did they get right and wrong?

Credit where it is due: the birth control pill concern is reasonable. Synthetic progestins in combined oral contraceptives are not the same as bioidentical progesterone, and the evidence on breast cancer risk with long-term OCP use is genuinely mixed. Morch et al. (2017, New England Journal of Medicine) found a small but real increased breast cancer risk with current or recent hormonal contraceptive use. Using OCPs as long-term HRT in perimenopausal women is not standard practice for good reason.

The TSH-only thyroid critique has some merit. Relying solely on TSH misses subclinical dysfunction in some patients, and cortisol dysregulation can affect the hypothalamic-pituitary axis. However, her claim that elevated estrogen "decreases the free thyroid" is an oversimplification. Oral estrogen raises thyroid-binding globulin, which lowers free T4 transiently, but the body usually compensates. This is not the crisis she implies.

The most problematic claim is insisting she would never prescribe estrogen-only therapy to any woman, including those who have had a hysterectomy. Current clinical guidelines from the Menopause Society (formerly NAMS) explicitly support estrogen-only therapy for women without a uterus, because they face no endometrial cancer risk and the data do not show elevated breast cancer risk from estrogen alone. Telling this group they should not take estrogen-only therapy is contradicted by evidence.

What should you actually know?

Transdermal estradiol is widely preferred by many menopause specialists over oral estrogen, partly because it avoids first-pass liver metabolism and has a better cardiovascular risk profile. That is a reasonable clinical preference backed by data, including the ESTHER study (Canonico et al., 2007, Circulation). But "never" is a strong word, and some women do fine on oral estradiol.

Estrogen-only therapy for women who have had a hysterectomy is supported by guidelines and by the WHI data. The risk picture changes meaningfully when you add a progestin, which is why the type of progestin matters. Micronized progesterone carries a more favorable safety profile than synthetic progestins, per the E3N data (Fournier et al., 2008, Breast Cancer Research and Treatment).

Her lifestyle points are not wrong. Endocrine disruptors, sleep deprivation, and chronic stress do affect hormone metabolism. But framing a prescription as insufficient without lifestyle changes, while never mentioning that untreated menopause symptoms have their own health consequences, leaves out an important half of the conversation. Women deserve the full picture, not a list of things one practitioner refuses to do.